CureVac (NASDAQ:CVAC) shares were up 2.6% on Thursday . The stock traded as high as $55.20 and last traded at $55.09. Approximately 217 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 1,152,690 shares. The stock had previously closed at $53.67.
Several equities analysts have issued reports on the company. Credit Suisse Group assumed coverage on CureVac in a research note on Monday, April 26th. They issued an “underperform” rating on the stock. Bank of America lowered CureVac from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research note on Thursday, June 17th. Berenberg Bank set a $123.00 target price on CureVac and gave the company a “buy” rating in a research note on Thursday, July 1st. Guggenheim initiated coverage on CureVac in a report on Monday, May 3rd. They set a “buy” rating for the company. Finally, Zacks Investment Research upgraded CureVac from a “sell” rating to a “hold” rating in a report on Friday, July 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $80.80.
The company has a market capitalization of $10.17 billion and a P/E ratio of -49.19. The company has a current ratio of 5.61, a quick ratio of 5.55 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $84.70.
About CureVac (NASDAQ:CVAC)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.